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Abstract 
Transforming growth factor β (TGF-β) can mediate proteoglycan synthesis via Smad and non-
Smad signalling pathways in vascular smooth muscle. We investigated whether TGF-β 
mediated proteoglycan synthesis is via PI3K/Akt. TGF-β induced a rapid phosphorylation of 
Akt that continued up to 4h. Akt phosphorylation was blocked by Akt1/2 inhibitor SN30978 
however it did not block Smad2 phosphorylation at either the carboxy or linker regions 
indicating that TGF-β-mediated Akt phosphorylation is independent of Smad2 signalling. The 
role of Akt in TGF-β-mediated proteoglycan synthesis was investigated. Treatment with 
SN30978 showed a concentration-dependent decrease of TGF-β-mediated [35S]-sulfate and 
[35S]-Met/Cys incorporation into secreted proteoglycans however SDS-PAGE showed no 
change in biglycan size. In TGF-β treated cells biglycan mRNA levels increased by 40-100% 
by 24h and was significantly blocked by SN30978. Our findings demonstrate that Akt is a 
downstream signalling component of TGF-β-mediated biglycan core protein synthesis but not 
glycosaminoglycan chain hyperelongation in vascular smooth muscle. 
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Introduction 
Proteoglycans including biglycan accumulate in the extracellular matrix of 
atherosclerotic-prone artery walls in the early stages of atherosclerotic lesion 
development 1. Biglycan is synthesized predominantly by vascular smooth muscle 
cells (VSMCs) in the vessel wall and atherogenic lipoproteins (LDL) become trapped 
on the negatively charged covalently attached glycosaminoglycan (GAG) chains 
thereby exacerbating macrophage accumulation and progression of atherosclerotic 
lesions. Previously it has been demonstrated that transforming growth factor-β (TGF-
β) treatment of human VSMCs increases the expression of biglycan and causes 
marked elongation of its GAG chains with a subsequent increase in the binding of 
LDL 2, 3, 4, 5. In addition TGF-β-mediated GAG elongation on biglycan requires de 
novo protein transcription and translation 6.  
 
TGF-β signals via TGF-β receptors type I and type II (TβRI and TβRII) with ligand 
binding causing the formation of a heteromeric complex of TβRI and TβRII and 
resulting in the autophosphorylation and activation of TβRI 7. TβRI then 
phosphorylates Smad2 and Smad3 in their C-terminal region which enables 
heterocomplex formation with Smad4 and subsequent translocation to the nucleus 
where they act as transcription factors binding to TGF-β responsive genes 8, 9. The 
canonical TGF-β-mediated Smad2/3 C-terminal phosphorylation is important in many 
TGF-β responses including biglycan synthesis and GAG chain elongation in VSM 4. 
However it has also been established that TGF-β can mediate pathways other than the 
canonical Smad pathway to generate proteoglycan synthesis. TGF-β-mediated 
phosphorylation of Smad2 linker region, described in the literature as a non-Smad 
pathway despite the integral role of Smad, has been shown to lead to activation of the 
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ERK and p38 MAP kinase signalling pathways and results in biglycan synthesis and 
GAG elongation in human VSMCs 2. In other contexts TGF-β-mediated 
phosphorylation of Smad linker region involves ERK and JNK MAP kinases 10 
however in VSMCs TGF-β causes JNK phosphorylation without effect on 
proteoglycan synthesis 2.  
 
Recently TGF-β signalling has been shown to involve Akt via activation of the PI3K-
Akt-TOR-S6 kinase pathway in cells undergoing epithelial to mesenchymal transition 
11. This activation has been shown to be independent of Smad2/3 in fibroblasts 12. 
Akt, also referred to as PKB, plays a key role in regulating cell survival and apoptosis 
13, 14. This protein kinase is activated by insulin and various growth factors in a 
wortmannin-sensitive pathway involving PI3 kinase 14. Akt binds phospholipid and is 
activated by phosphorylation by PDK1 at Thr308 in the activation loop and by PDK2 
at Ser473 at the carboxy terminus 15. Akt inhibits apoptosis by phosphorylating and 
inactivating Bad 16, forkhead transcription factors 17, c-Raf 18 and caspase-9. Akt also 
regulates glycogen synthesis through phosphorylation and inactivation of GSK-3α and 
β 19. In cell cycle regulation Akt prevents GSK-3β mediated phosphorylation and 
degradation of cyclin D1 20 and negatively regulates the cyclin dependent kinase 
inhibitors p27 Kip 21 and p21 Waf1/CIP1 22. Akt also plays a critical role in cell 
growth by directly phosphorylating mTOR and tuberin (TSC2), an inhibitor of 
mTOR, in a rapamycin-sensitive complex containing raptor 23. Inhibition of mTOR 
blocks protein synthesis and translation 24.  
 
Clearly Akt has key roles in EMT, cell cycle regulation, cell growth and cell survival 
in many cell types. TGF-β-mediated activation of PI3K/Akt pathway can complement 
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or antagonize Smad-mediated effects depending on cell type and context. In this study 
we have investigated whether TGF-β can activate Akt and its requirement for Smad in 
biglycan synthesis in human VSMCs. 
 
Materials and methods 
Materials 
The following chemicals were purchased from Sigma, (St Louis, MO, USA): 
benzamidine hydrochloride, DEAE-Sephacel, Sepharose CL-6B, proteinase K, 
chondroitin sulfate, SB431542, PDGF, thrombin and penicillin-streptomycin. 
Recombinant TGF-1 was from R&D Systems Inc. (Minneapolis, USA). SN30978 
was a kind gift from Dr. Graeme Lancaster (BakerIDI, Melbourne, Australia). 
Dulbecco’s modified eagle medium (DMEM), glutamine, fetal bovine serum (FBS) 
were purchased from Invitrogen. Rainbow [14C] methylated protein molecular weight 
standards (Amersham Pharmacia, Buckinghamshire, England). Cetyl pyridinium 
chloride (CPC) was from Unilab Chemicals and Pharmaceuticals, India. Whatman 
3MM chromatography paper was from Biolab (Mulgrave, Australia), Instagel Plus 
scintillation fluid, [35S]Sulfate and [35S]-Met/Cys were from Perkin-Elmer (Waltham, 
MA, USA) and Poly-Prep columns from Bio-Rad (Hercules, CA USA).. 
 
Culture of human VSMC 
Human VSMCs were prepared by the explant method as previously described 25 
using otherwise discarded sections of the internal mammary artery and saphenous 
veins from patients undergoing coronary artery bypass grafting at Alfred Health, 
Melbourne, Australia. The acquisition of the vessel segments was approved by the 
Alfred Hospital Ethics committee. VSMC were grown in Dulbecco’s modified eagle 
medium (DMEM) with 5mM glucose, 10% FBS and 1% penicillin-streptomycin 
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solution. For experimentation, VSMC were seeded into 24 well plates (proteoglycan 
experiments) or 60 mm diameter plates (Western blotting experiments), grown until 
confluency then serum starved (0.1% FCS) for 48 h before experimentation as 
described. 
 
Western blotting 
Total cell lysates were resolved on 10% SDS-PAGE and transferred onto PVDF 
membranes. Membranes were blocked with 5% skim milk powder, incubated with 
primary antibodies as detailed in the text followed by HRP-anti-rabbit IgG and ECL 
detection (Amersham). Blots were quantified by densitometry using QuantityOne 
software (BioRad). Primary antibodies used in this study were anti-phosphoSmad2/3C 
rabbit monoclonal antibody, anti-phosphoSmad2L, antibody anti-phosphoAkt 
(phosphoThr308) antibody, anti-Akt1/2/3 antibody, anti-GAPDH antibody (Cell 
Signaling Technology, MA, USA) 
 
Quantitation of proteoglycan synthesis 
Quiescent cells were changed to fresh medium containing 25 μCi/mL of [35S]sulfate 
in the presence or absence of TGF-β1 for 24 hours. Media from the cell cultures was 
harvested with added protease inhibitors (5mM Benzamidine in 0.1M 6-aminocaproic 
acid). Incorporation of the radiolabel into proteoglycans was measured by CPC 
precipitation assay as described previously 26. 
 
SDS-PAGE analysis of proteoglycan size 
Proteoglycans labelled with [35S]sulfate or [35S]-Met/Cys were prepared for SDS-
PAGE by isolation through DEAE sephacel anionic exchange mini columns. Samples 
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were added to pre-equilibrated columns, then washed extensively with low salt buffer 
(8M Urea, 0.25M NaCl, 2 mM disodium EDTA, 0.5% Triton X-100). Proteoglycans 
were eluted with high salt buffer (8M Urea, 3M NaCl, 2mM disodium EDTA, 0.5% 
Triton X-100) Aliquots (25,000 cpm) were precipitated (1.3% potassium acetate, 95% 
ethanol) and chondroitin sulfate was added as a cold carrier. Samples were 
resuspended in buffer (8M Urea, 2mM disodium EDTA, pH 7.5), to which an equal 
volume of sample buffer was added. Radiolabelled proteoglycans were separated on 
4-13% acrylamide gels with a 3% stacking gel at 50V overnight. [14C]-protein 
molecular weight markers were run simultaneously. Processed and dried gels were 
exposed to a phosphoimaging screen (Fuji Photo Film Co, Japan) for approximately 3 
days, then scanned on a Bio-imaging analyser BAS-1000 MacBas (Fuji Photo Film 
Co, Japan). 
 
Determination of the expression of biglycan by RT-PCR 
Human VSMCs cells were plated on 6-well culture plate pre-coated with 10 ug/ml 
poly-D-lysine and fed with DMEM medium supplemented with 1% FBS, plus 
antibiotics in 5% CO2 at 37oC. The following day medium was replaced with DMEM 
alone for 1h then the cells were treated with TGFβ (2ng/ml) for different times as 
indicated to observe the effect of TGFβ on the expression of biglycan. In experiments 
using inhibitors, cells were pre-incubated with or without SN30978 (5 µM) or 
SB431542 (3µM) for 30min, and then treated with TGF-β (2ng/ml) for 24 hours. 
Total RNAs were extracted from treated cells using TRIZOL Reagent (TIANGEN 
Corp.). First-strand cDNA was synthesized from 1.5 μg total RNA with random 
primer and M-MLV RTase (Genecopoeia Corp.); Resulting cDNA were subjected to 
PCR amplification using specific primers (sense primer, 5’-
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CTCCTCCAGGTGGTCTATC-3’and antisense primer, 5’-
GCTGATGCCGTTGTAGTAG-3’) for biglycan. Products of PCR were 
electrophoresed on a 1.5% agarose gel. 
 
Statistical analyses 
Data was analysed for statistical significance using a 1-way analysis of variance 
(ANOVA) or a Student’s paired t-test as stated. Results were considered statistically 
significant at P<0.05 or better as stated. 
 
Results 
TGF-β causes rapid phosphorylation of Akt in human VSMCs 
To determine whether TGF-β can elicit phosphorylation of Akt in VSMCs we treated 
serum-deprived human VSMCs with TGF-β (2 ng/ml) for 0 – 4h and then probed a 
western blot of whole cell lysates with anti-pAkt antibody (Figure 1). TGF-β 
mediated a rapid phosphorylation of Akt Ser473 within 5 mins (Figure 1A) and 
elevated levels were maintained up to 4h (Figure 1B). Time-course western blots 
probed with antibody to pAkt Thr308 gave the same results (data not shown). PDGF 
(50 ng/ml) was used as a positive control because of its ability to phosphorylate Akt at 
both Ser473 and Thr308 in VSMCs within 5 mins and sustain elevated levels for 
several hours 27.  
 
TGF-β activates PI3K which in turn phosphorylates Akt on Ser473 and 
phosphoinositide-dependent kinase 1 (PDK1) a signalling component downstream of 
PI3K phosphorylates Akt Thr308. Phosphorylation can be inhibited by the allosteric 
non-ATP competitive Akt1/2 inhibitor SN30978 28. Cells were treated for either 15 
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min or 4h with TGF-β in the absence or presence of SN30978 (Figure 2A). Akt 
phosphorylation was completely blocked by a 30 min pre-incubation of SN30978 (2 
µM) at both treatment times (Figure 2A). Therefore TGF-β activates PI3K signalling 
that leads to pAkt in VSMCs. Blocking TβRI activity with its specific inhibitor 
SB431542 29 reduced pAkt levels to basal (Figure 2B) demonstrating the requirement 
for TβRI upstream of Akt phosphorylation. Previously we have reported that both 
thrombin and PDGF mediated proteoglycan core protein synthesis in VSMCs involve 
PI3K activity 30. To determine whether Akt is phosphorylated downstream of PDGF 
or thrombin activation we treated cells with PDGF for 1h and observed a marked 
elevation of pAkt levels above basal indeed they were higher than the level generated 
by TGF-β treatment (Figure 2B). Thrombin stimulation of pAkt was close to basal 
levels at this time point. When we pre-treated cells with SN30978 and stimulated with 
PDGF or thrombin there was minimal generation of pAkt (Figure 2B) suggesting that 
PI3K/Akt are downstream of all three agonists in VSMCs but to different extents. 
 
TGF-β-mediated Smad2 phosphorylation is independent of Akt stimulation  
Smad-independent TGF-β signalling of PI3K has been reported in fibroblasts 12 and 
here we investigated whether blocking phosphorylation of Akt would interfere with 
the known pathway of TGF-β/carboxy terminal and linker region phosphorylation of 
Smad2 2, 4. TGF-β induces TβRI to directly phosphorylate the two distal serines of 
Smad C-terminal SSXS motif and indirectly cause MAP kinases to phosphorylate 
serine and threonine residues in Smad linker region 8. Western blots using anti-
pSmad2C showed a significant increase (4.6-fold) in pSmad2C levels following TGF-
β treatment (Figure 3A and 3B). PDGF and thrombin showed a small increase in 
pSmad2C levels above basal the latter similar to our published findings 31. Blocking 
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Akt phosphorylation had no effect on pSmad2C levels after stimulation with any of 
the agonists (Figure 3A). TGF-β treatment increased the level of Smad2 linker region 
phosphorylation approximately 5-fold compared to a 2-fold or less increase after 
PDGF or thrombin stimulation respectively (Figure 3B). Similarly to pSmad2C we 
observed no change in the levels of pSmad2L when Akt phosphorylation was blocked 
with SN30978 (Figure 3B). The inability of the Akt inhibitor to block Smad 
phosphorylation indicates that neither carboxy nor linker region Smad2 
phosphorylation are downstream of Akt and in this context are likely independent of 
PI3K activation. 
 
TGF-β stimulates biglycan core protein synthesis via Akt 
To determine whether Akt is a component of TGF-β-mediated proteoglycan synthesis 
in human VSMCs we performed experiments with the Akt1/2 inhibitor SN30978 on 
radiolabelled [35S]-sulfate incorporation into proteoglycans in TGF-β treated cells. 
Figure 4 shows cells treated with TGF-β had a 2-3-fold increase in [35S]-sulfate into 
secreted proteoglycans, in these cells predominantly biglycan, compared to controls. 
Treatment with SN30978 (0 – 3 µM) showed a concentration-dependent decrease of 
TGF-β-mediated [35S]-sulfate incorporation into secreted proteoglycans (Figure 4A) 
with a maximal 41 % decrease at 3 µM. The TβRI inhibitor SB431542 29 was used as 
a positive control. SDS-PAGE of the secreted proteoglycans showed no change in the 
size of the biglycan band at any concentration of the Akt inhibitor (Figure 4B). While 
proteoglycan core protein size remains fixed, GAG chains can vary in length and are 
altered by a variety of growth factors 6. The current findings show that Akt is not 
involved in TGF-β-mediated proteoglycan GAG chain hyperelongation. 
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To assess changes in proteoglycan core protein synthesis we labelled proteoglycans 
with [35S]-Met/Cys for 24h and quantitated incorporated radiolabel in secreted 
proteoglycans. TGF-β stimulated cells showed an increase of approximately 20% in 
[35S]-Met/Cys incorporation compared to control (Figure 4C). Treatment of cells with 
SN30978 showed a dose-dependent decrease in TGF-β-mediated [35S]-Met/Cys 
incorporation with the level close to basal amounts at the maximal concentration 
tested (Figure 4C). To specifically examine biglycan core protein expression we 
measured the levels of biglycan mRNA in TGF-β treated VSMCs. Biglycan mRNA 
levels increased over 24h from an increase of 1.75-fold at 3h to a maximum of 2-fold 
at 24h (Figure 5). In the presence of SN30978 there was a significant block of TGF-β-
mediated increase of biglycan mRNA (Figure 6, TGF-β, 24h) which verifies that Akt 
is a downstream mediator of TGF-β-stimulated biglycan core protein synthesis in 
VSMCs. 
 
Discussion 
TGF-β is a potent regulator of extracellular matrix synthesis including proteoglycan 
synthesis in the blood vessel wall 2, 3, 4, 5, 32. In vascular smooth muscle TGF-β 
upregulates biglycan expression and hyperelongation of its chondroitin sulfate GAG 
chains leading to increased binding to LDL with consequent increased lipid retention 
and accelerated atherosclerosis 5, 33. The signalling pathways from TGF-β to the 
synthesis of proteoglycans are only partially described and are cell and context 
dependent. In this study we examined whether TGF-β-mediated activation of the 
PI3K/Akt pathway in human VSMCs and to what extent the pathway is involved in 
proteoglycan synthesis. We demonstrated that TGF-β stimulated Akt phosphorylation 
within 5 mins and continued for at least 24h (see Figure 1) comparable to the response 
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observed recently in cardiac fibroblasts 34. TGF-β mediates a slower time course of 
Akt phosphorylation in hypoxic pulmonary artery smooth muscle cells 35, mesangial 
cells 36 and fibroblasts 37 and reflects the different cell contexts of TGF-β signalling.  
 
Our previous studies have shown that in VSMCs TGF-β causes proteoglycan 
synthesis via both Smad-dependent 4 and MAP kinase/Smad linker-dependent 
pathways 2. Our results in the current study showed that blocking Akt phosphorylation 
did not alter the level of Smad2 phosphorylation at either the C-terminal SXSS motif 
or the linker region serine residues (see Figure 3) and Smad2 phosphorylation appears 
independent of PI3K/Akt activation. Our findings are in agreement with reports of 
TGF-β regulating Smad2 and Smad3 and PI3K responses independently 12. Other 
reports suggest the PI3K and Smad signalling pathways may be connected with 
Smad3 inhibition reducing TGF-β-mediated activation of Akt 34 and PI3K inhibition 
decreasing Smad3 activity 38. While we cannot ignore the possibility that Smad3 may 
signal differently to Smad2 our work has focussed on the latter transcription factor 
because to date we have no evidence to suggest a role for involvement of Smad3 in 
proteoglycan synthesis in VSMCs (unpublished observation). The exact mechanism 
of TGF-β induced Akt phosphorylation in human VSMCs warrants further 
investigation. 
 
Growth factor activation of the PI3K/Akt pathway upregulates extracellular matrix 
components including collagen via TGF-β 34 and proteoglycans via IGF139 and 
aggrecan and versican via IGF2 40 and GAG synthesis in fetal lung fibroblasts via 
PDGF 41. In VSMCs TGF-β mediates proteoglycan synthesis via the Akt pathway 
(see Figure 4) as demonstrated by dose-dependently blocking [35S]-sulfate and [35S]-
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Met/Cys incorporation into proteoglycans with SN30978. We determined that Akt 
signalling does not affect GAG synthesis as there is no detectable change in biglycan 
GAG length when this pathway is inhibited (Figure 4). Biglycan core protein 
synthesis is dependent on Akt phosphorylation demonstrated by the ability of the Akt 
inhibitor to block TGF-β mediated increase in biglycan mRNA (see Figure 6) and 
incorporation of [35S]-Met/Cys into core protein (see Figure 4). The TβRI inhibitor 
SB431542 blocks proteoglycan chain elongation independently of core protein 
synthesis 4. Here we saw SN30978 only able to block Akt-mediated biglycan core 
protein synthesis not chain elongation demonstrating that at least two signalling 
pathways may be involved in biglycan core protein synthesis. Interestingly in human 
chondrocytes IGF2 upregulates aggrecan and versican mRNA levels via Akt 40 
however IGF1 has no effect via Akt on aggrecan, decorin or biglycan core protein 
mRNA levels 39. Similarly Akt signalling results in different outcomes in GAG 
synthesis with our results showing TGF-mediated phosphorylation of Akt not altering 
biglycan GAG synthesis but PDGF-mediated Akt activation reported to have an 
integral role in GAG regulation in fetal lung fibroblasts 42. The diversity of effects 
suggests differences and complexity reflecting not only cell type but also the 
activating growth factor and its downstream outputs. 
 
Conclusions 
We have demonstrated that Akt is an active component of TGF-mediated signalling to 
biglycan core protein synthesis in human vascular smooth muscle cells. In contrast 
TGF-β-induced proteoglycan GAG chain hyperelongation does not require Akt 
phosphorylation. Akt signalling pathways are important in many cellular contexts and 
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further investigations are warranted to determine whether Akt instigates changes in 
other proteoglycan related cellular processes and in other cell types.  
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Figure Legends 
Figure 1 Time-course of TGF-β mediated phosphorylation of Akt in human 
VSMCs. Human VSMC were or untreated (-) or treated with TGF-β (2 ng/ml) for (A) 
0 – 30 mins and (B) 0 - 360 mins. PDGF (50 ng/ml)-treated VSMCs were used as a 
positive control. Whole cell protein lysates were resolved by 10% SDS-PAGE gels 
and transferred to PVDF membranes. Membranes were probed with primary anti-
phospho-Akt (pAkt, Ser473) antibody and visualised with ECL. Blots were stripped 
and re-probed for total Akt (Akt) and GAPDH for loading controls. 
 
Figure 2 Akt1/2 inhibitor completely blocks TGF-β mediated phosphorylation of 
Akt. 
Cells were untreated (-) or pre-treated for 30 min with the Akt1/2 inhibitor SN30978 
(2 µM) and then stimulated with (A) TGF-β (2 ng/ml) for either 15 min or 4 h, or 
PDGF (50 ng/ml) for 1 h (B) Thrombin (10 Units/ml), PDGF (50 ng/ml) or TGF-β (2 
ng/ml) for 1 h. Cells pre-treated for 30 min with TβRI kinase inhibitor SB431542 (3 
µM) (SB) were stimulated with TGF-β (2 ng/ml) for 1 h. Cell lysates were processed 
and probed for phospho-Akt, Akt and GAPDH as described. Density analysis using 
Biorad Quantity One software is shown to the right of each blot, ## P<0.01 vs control, 
** P<0.01 vs agonist, # P<0.05 vs control 
 
Figure 3 Role of Akt in TGF-β-mediated Smad pathway 
Cells were untreated (-) or pre-treated for 30 min with the Akt1/2 inhibitor SN30978 
(2 µM) and then stimulated with Thrombin (10 Units/ml), PDGF (50 ng/ml) or TGF-β 
(2 ng/ml) for 1 h. Cells pre-treated for 30 min with TβRI kinase inhibitor SB431542 
(3 µM) (SB) were stimulated with TGF-β (2 ng/ml) for 1 h. Cell lysates were 
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processed as described (see Figure 1 legend) and probed with (A) anti-phospho-
Smad2 carboxy terminal antibody (pSmad2C) or (B) anti-phospho-Smad2 linker 
region antibody (pSmad2L) and GAPDH. Density analysis using Biorad Quantity 
One software is shown for each blot (B) pSmad2C and (C) pSmad2L, ## P<0.01 vs 
control, ** P<0.01 vs agonist. 
 
Figure 4 Role of Akt in TGF-β-mediated proteoglycan synthesis in human 
VSMCs. 
VSMCs were pre-treated for 30 min with SN30978 (0 – 3 µM) or SB431542 (3 µM) 
(SB) and then stimulated with TGF-β (2 ng/ml) for 24 h in the presence of [35S]-
sulfate or [35S]-Met/Cys for 24 h. (A) [35S]-sulfate incorporation (B) SDS-PAGE 
analysis of [35S]-sulfate incorporated samples (C) [35S]-Met/Cys incorporation into 
proteoglycan core protein synthesis. Histogram values are expressed as percentage of 
untreated control value, ## P<0.01 vs control, ** P<0.01 vs agonist. 
 
Figure 5 TGF-β-induced changes in biglycan mRNA levels in human VSMCs. 
Human VSMCs were treated with TGF-β (2 ng.ml) for various times (0 – 24 h), and 
the expressions of  biglycan were determined by RT-PCR as described in Material 
and Method. RPL is ribosomal protein mRNA. TGF-β time-dependently induced the 
expression of  biglycan in human VSMCs cells. The relative mRNA level was 
normalised to the level of untreated control cells. ## P<0.01 vs control. Results are 
from four independent experiments.  
 
Figure 6 Effects of Akt inhibitor SN30978 on biglycan mRNA levels. 
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VSMCs pre-treated with or without SN30978 (5 µM) or SB431542 (3 µM)for 30 min 
were stimulated with TGF-β (2 ng.ml) for 24 h, and levels of biglycan mRNA 
measured. Both SN30978  and  SB431542 blocked TGF-β-induced expression of 
biglycan in VSMCs.  The relative mRNA level was normalised to the level of 
untreated control cells (-).** P<0.01 vs agonist, *P<0.05 vs agonist, # P<0.05 vs 
control. Results are from three independent experiments.  
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